Cell Dissociation Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Cell Dissociation Market Report is Segmented by Product (Enzymatic Dissociation Products, and More), Tissue (Connective Tissue, Epithelial Tissue, Muscular Tissue, and More), End-User (Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Cell Dissociation Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Cell Dissociation Market with other markets in Healthcare Industry

Cell Dissociation Market Analysis by Mordor Intelligence

The cell dissociation market is valued at USD 0.61 billion in 2025 and is projected to reach USD 1.24 billion by 2030, expanding at a 15.17% CAGR. The market’s ascent is tied to its enabling role in cell and gene therapy production, single-cell omics, and personalized-medicine pipelines. Regulatory approvals for advanced therapies, automation breakthroughs, and large-scale public biotechnology funding collectively accelerate adoption. Pharmaceutical and biotechnology firms remain the primary purchasers, yet contract research organizations (CROs) capture rising share as sponsors outsource complex tasks. North America keeps the lead owing to established infrastructure, while Asia-Pacific posts the fastest growth backed by multibillion-dollar national programs in China, Japan, and India.

Key Report Takeaways

  • By product category, enzymatic reagents led with 58.76% of cell dissociation market share in 2024, whereas non-enzymatic products are projected to expand at 17.67% CAGR through 2030.
  • By tissue type, connective tissue commanded 41.45% of cell dissociation market size in 2024; tumor and organoid applications advance at 17.99% CAGR to 2030.
  • By end-user, pharmaceutical and biotechnology companies held 46.65% of cell dissociation market size in 2024, while CROs register the highest 18.65% CAGR through 2030.
  • By geography, North America accounted for 38.78% of cell dissociation market share in 2024, whereas Asia-Pacific is forecast to post a 16.56% CAGR between 2025-2030.

Segment Analysis

By Product: Non-Enzymatic Solutions Drive Innovation

Enzymatic reagents retained 58.76% share in 2024, with bacterial collagenase from Clostridium histolyticum prized for specificity. Trypsin dominates routine passaging, while dispase and elastase service niche applications. Non-enzymatic formulations post the fastest 17.67% CAGR as single-cell workflows shy away from protease exposure[2]ATCC, “Animal-Component-Free Cell Dissociation Solution,” atcc.org. ATCC’s chelator-based solution and recombinant TrypLE exemplify this regulatory-friendly shift. Automated tissue dissociators now come bundled with reagent cartridges to minimize operator variability.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Tissue: Tumor Applications Lead Growth

Connective tissue captured 41.45% of market share in 2024 thanks to well-standardized collagenase protocols across liver and lung studies. Tumor and organoid samples log the highest 17.99% CAGR, with electric-field-assisted workflows achieving 95% tissue dissociation in under five minutes while maintaining viability. Mouse mammary tumor methods now reach 90% viable cell recovery for single-cell transcriptomic analysis.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By End-User: CROs Experience Rapid Expansion

Pharmaceutical and biotech firms retained 46.65% market share in 2024 but CROs rise fastest at 18.65% CAGR thanks to capacity constraints at large sponsors. Contract manufacturing held 67.13% of the USD 9.95 billion 2023 cell-and-gene-therapy production market, highlighting outsourcing momentum. Charles River’s acquisition of Cognate BioServices typifies vertical integration of development and GMP supply.

Geography Analysis

North America held 38.78% of market share in 2024, buoyed by FDA fast-track pathways for advanced therapies. New York’s USD 430 million BioGenesis Park adds 1,530 jobs and new GMP suites[3]New York State Governor, “BioGenesis Park Secures USD 430 Million Funding,” governor.ny.gov. Canada’s USD 22.5 million investment in STEMCELL Technologies ensures domestic reagent capacity. Sartorius and Siemens collaborate on digital-twin automation that trims lot-release time.

Asia-Pacific advances at 16.56% CAGR, led by China’s USD 4.17 billion biopark program. Japan’s Startup Development Five-Year Plan and aging-society needs push biotech growth toward ¥15 trillion by 2030. India’s BioE3 policy aims to position local CDMOs as global suppliers in anticipation of supply-chain diversification from U.S. Biosecure Act compliance.

Europe benefits from the EU biotechnology strategy targeting greater participation in the EUR 720 billion global market. EMA guidelines for cell-based products and new European Pharmacopoeia QC chapters provide regulatory clarity. Lonza’s Dutch plant produces CASGEVY for Vertex, underscoring Europe’s relevance as a high-volume contract-manufacturing hub.

Cell Dissociation Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Thermo Fisher Scientific dominates through broad reagent lines and plans USD 40-50 billion in acquisitions targeting complementary technologies. BD will spin off its Biosciences and Diagnostics arm into a USD 3.4 billion life-science tools specialist to sharpen focus on growth areas. Sartorius’ CellCelector Flex and Siemens’ digital-twin automation deliver end-to-end solutions that minimize labor and increase consistency. Miltenyi Biotec leverages MACS technology to enable point-of-care manufacturing at hospital sites. Enzyme suppliers lock in long-term contracts to hedge against shortages, while microfluidic start-ups launch chip-based dissociators aimed at single-cell labs.

Cell Dissociation Industry Leaders

  1. Thermo Fisher Scientific, Inc.

  2. Becton, Dickinson And Company

  3. Merck KGaA

  4. Miltenyi Biotec

  5. STEMCELL Technologies

  6. *Disclaimer: Major Players sorted in no particular order
Cell Dissociation Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: Thermo Fisher unveiled Orbitrap Astral Zoom and Excedion Pro mass spectrometers at ASMS 2025.
  • May 2025: BD introduced the FACSDiscover A8 Cell Analyzer with real-time imaging and spectral flow capabilities.
  • May 2025: Sartorius launched the Octet R8e biolayer interferometer for rapid, label-free binding analysis.
  • April 2025: Thermo Fisher released the 5 L DynaDrive single-use bioreactor, boosting cell-culture productivity by 27%.
  • February 2025: Aurora Biosynthetics debuted in Asia-Pacific via an AU$200 million RNA-manufacturing alliance.

Table of Contents for Cell Dissociation Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Expansion of Cell and Gene Therapy Pipelines
    • 4.2.2 Rising Adoption of Single-Cell Omics Technologies
    • 4.2.3 Surge In Biomanufacturing for Personalized Medicine
    • 4.2.4 Growing Investments in Regenerative Medicine Research
    • 4.2.5 Increasing DemandfFor High-Throughput Automation
    • 4.2.6 Government Initiatives to Strengthen Biotechnology Infrastructure
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Advanced Dissociation Technologies
    • 4.3.2 Variability and Standardization Challenges
    • 4.3.3 Stringent Regulatory and Validation Requirements
    • 4.3.4 Limited Availability of GMP-Grade Enzymes
  • 4.4 Regulatory Landscape
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Bargaining Power Of Buyers/Consumers
    • 4.5.2 Bargaining Power Of Suppliers
    • 4.5.3 Threat Of New Entrants
    • 4.5.4 Threat Of Substitute Products
    • 4.5.5 Intensity Of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product
    • 5.1.1 Enzymatic Dissociation Products
    • 5.1.1.1 Collagenase
    • 5.1.1.2 Trypsin
    • 5.1.1.3 Papain
    • 5.1.1.4 Dispase
    • 5.1.1.5 Elastase & Hyaluronidase
    • 5.1.2 Non-Enzymatic Dissociation Products
    • 5.1.2.1 Chelating Agents
    • 5.1.2.2 Recombinant Enzyme-Free Solutions (Accutase, TrypLE)
    • 5.1.2.3 Mechanical Dissociation Kits & Filters
    • 5.1.3 Instruments & Accessories
    • 5.1.3.1 Automated Tissue Dissociators
    • 5.1.3.2 Microfluidic Dissociation Devices
    • 5.1.3.3 Cell Strainers & Filtration Units
    • 5.1.3.4 Consumable Accessories (Tubes, Rotors)
  • 5.2 By Tissue
    • 5.2.1 Connective Tissue
    • 5.2.2 Epithelial Tissue
    • 5.2.3 Muscular Tissue
    • 5.2.4 Nervous Tissue
    • 5.2.5 Tumor & Organoid Samples
  • 5.3 By End-User
    • 5.3.1 Pharmaceutical & Biotechnology Companies
    • 5.3.2 Research & Academic Institutes
    • 5.3.3 Contract Research Organizations
    • 5.3.4 Hospitals & Diagnostic Laboratories
    • 5.3.5 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Thermo Fisher Scientific, Inc.
    • 6.3.2 Becton, Dickinson And Company
    • 6.3.3 Merck KGaA
    • 6.3.4 Miltenyi Biotec
    • 6.3.5 F. Hoffmann-La Roche Ltd
    • 6.3.6 GE Healthcare
    • 6.3.7 American Type Culture Collection (ATCC)
    • 6.3.8 STEMCELL Technologies
    • 6.3.9 HiMedia Laboratories
    • 6.3.10 Pan-Biotech
    • 6.3.11 Worthington Biochemical Corporation
    • 6.3.12 Danaher Corporation
    • 6.3.13 Corning Incorporated
    • 6.3.14 Lonza Group
    • 6.3.15 Sartorius AG
    • 6.3.16 Takara Bio Inc.
    • 6.3.17 Bio-Rad Laboratories
    • 6.3.18 Advanced Cell Diagnostics (Bio-Techne)
    • 6.3.19 TissueGnostics
    • 6.3.20 CellData Sciences

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Cell Dissociation Market Report Scope

Cell dissociation refers to the act of separating adherent cell monolayers into single-cell suspensions. The cell dissociation process has tremendous application in regenerative medicine and stem cell research. The cell dissociation products are either enzyme-based or non-enzymatic buffers.

The cell dissociation market is segmented by product, tissue, end user, and geography. By product, the market is sub-segmented into enzymatic dissociation products, non-enzymatic dissociation products, instruments, and accessories. By tissue, the market is sub-segmented into connective tissue, epithelial tissue, and other tissues. By end user, the market is sub-segmented into pharmaceutical and biotechnology companies, research and academic institutes, and other end users. By geography, the market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for all the above segments.

By Product Enzymatic Dissociation Products Collagenase
Trypsin
Papain
Dispase
Elastase & Hyaluronidase
Non-Enzymatic Dissociation Products Chelating Agents
Recombinant Enzyme-Free Solutions (Accutase, TrypLE)
Mechanical Dissociation Kits & Filters
Instruments & Accessories Automated Tissue Dissociators
Microfluidic Dissociation Devices
Cell Strainers & Filtration Units
Consumable Accessories (Tubes, Rotors)
By Tissue Connective Tissue
Epithelial Tissue
Muscular Tissue
Nervous Tissue
Tumor & Organoid Samples
By End-User Pharmaceutical & Biotechnology Companies
Research & Academic Institutes
Contract Research Organizations
Hospitals & Diagnostic Laboratories
Other End-Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product
Enzymatic Dissociation Products Collagenase
Trypsin
Papain
Dispase
Elastase & Hyaluronidase
Non-Enzymatic Dissociation Products Chelating Agents
Recombinant Enzyme-Free Solutions (Accutase, TrypLE)
Mechanical Dissociation Kits & Filters
Instruments & Accessories Automated Tissue Dissociators
Microfluidic Dissociation Devices
Cell Strainers & Filtration Units
Consumable Accessories (Tubes, Rotors)
By Tissue
Connective Tissue
Epithelial Tissue
Muscular Tissue
Nervous Tissue
Tumor & Organoid Samples
By End-User
Pharmaceutical & Biotechnology Companies
Research & Academic Institutes
Contract Research Organizations
Hospitals & Diagnostic Laboratories
Other End-Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How large is the cell dissociation market in 2025 and what is its growth outlook?

The cell dissociation market is valued at USD 0.61 billion in 2025 and is projected to reach USD 1.24 billion by 2030, advancing at a 15.17% CAGR.

Which product category leads the cell dissociation market?

Enzymatic reagents lead, accounting for 58.76% of cell dissociation market share in 2024, largely due to their well-established efficacy in a wide range of tissues.

What is driving the rapid growth of non-enzymatic dissociation solutions?

Non-enzymatic products grow at a 17.67% CAGR because single-cell omics and immunophenotyping workflows demand gentler methods that preserve surface markers and gene-expression fidelity.

Why are CROs emerging as the fastest-growing end-user segment?

CROs post an 18.65% CAGR as pharmaceutical companies outsource complex cell-therapy process development and manufacturing to specialized partners with dedicated capacity.

Which region shows the highest growth, and why?

Asia-Pacific demonstrates the fastest 16.56% CAGR through 2030, supported by multi-billion-dollar government investments, expanding clinical trial pipelines, and cost-advantaged manufacturing infrastructure.

What are the main restraints that could slow market expansion?

High capital costs for advanced automation and the challenge of standardizing protocols across variable tissue sources can shave up to 2.1% and 1.8% off the forecast CAGR, respectively.

Page last updated on: June 24, 2025

Cell Dissociation Market Report Snapshots